Plasmodium falciparum antigens and methods of use

Abstract

The subject invention provides novel Plasmodium falciparum antigens and novel polynucleotides encoding these antigens. Also provided by the subject invention are methods of using these antigens and polynucleotides.

1 . An isolated or purified polynucleotide:
 a) encoding a polypeptide comprising SEQ ID NO: 2;   b) encoding a Human Leukocyte Antigen (HLA) binding fragment of SEQ ID NO: 2, said fragment comprising at least five consecutive amino acids of SEQ ID NO: 2; or   c) that is complementary along the full length of said polynucleotide of a) or b).   
     
     
         2 . The isolated or purified polynucleotide according to  claim 1 , wherein said polynucleotide encodes said polypeptide comprising SEQ ID NO: 2. 
     
     
         3 . The isolated or purified polynucleotide according to  claim 1 , wherein said polynucleotide encodes said FILA binding fragment. 
     
     
         4 . The isolated or purified polynucleotide according to  claim 1 , wherein said polynucleotide is complementary along the full length of said polynucleotide of a). 
     
     
         5 . The isolated or purified polynucleotide according to  claim 1 , wherein said polynucleotide is complementary along the full length of said polynucleotide of b). 
     
     
         6 . A vector comprising a promoter operably linked to a polynucleotide:
 a) encoding a polypeptide comprising SEQ ID NO: 2;   b) encoding a Human Leukocyte Antigen (HLA) binding fragment of SEQ ID NO: 2, said fragment comprising at least five consecutive amino acids of SEQ ID NO: 2; or   c) that is complementary along the full length of said polynucleotide of a) or b).   
     
     
         7 . The vector according to  claim 6 , wherein said polynucleotide encodes said polypeptide comprising SEQ ID NO: 2. 
     
     
         8 . The vector according to  claim 6 , wherein said polynucleotide encodes said HLA biding fragment. 
     
     
         9 . The vector according to  claim 6 , wherein said polynucleotide is complementary along the full length of said polynucleotide of a). 
     
     
         10 . The vector according to  claim 6 , wherein said polynucleotide is complementary along the full length of said polynucleotide of b). 
     
     
         11 . An isolated transformed host cell comprising a polynucleotide:
 a) encoding a polypeptide comprising SEQ ID NO: 2;   b) encoding a Human Leukocyte Antigen (HLA) binding fragment of SEQ ID NO: 2, said fragment comprising at least five consecutive amino acids of SEQ ID NO: 2; or   c) that is complementary along the full length of said polynucleotide of a) or b).   
     
     
         12 . The isolated transformed host cell according to  claim 11 , wherein said polynucleotide encodes said polypeptide comprising SEQ ID NO: 2. 
     
     
         13 . The isolated transformed host cell according to  claim 11 , wherein said polynucleotide encodes said HLA binding fragment. 
     
     
         14 . The isolated transformed host cell according to  claim 11 , wherein said polynucleotide is complementary along the full length of said polynucleotide of a). 
     
     
         15 . The isolated transformed host cell according to  claim 11 , wherein said polynucleotide is complementary along the full length of the polynucleotide of b). 
     
     
         16 . The isolated transformed host cell according to  claim 11 , wherein said polynucleotide is a vector comprising a promoter operably linked to a polynucleotide:
 a) encoding a polypeptide comprising SEQ ID NO: 2;   b) encoding a Human Leukocyte Antigen (HLA) binding fragment of SEQ ID NO: 2, said fragment comprising at least five consecutive amino acids of SEQ ID NO: 2; or   c) that is complementary along the full length of said polynucleotide of a) or b).   
     
     
         17 . The isolated transformed host cell according to  claim 16 , wherein said polynucleotide encodes said polypeptide comprising SEQ ID NO: 2. 
     
     
         18 . The isolated transformed host cell according to  claim 16 , wherein said polynucleotide encodes said HLA binding fragment. 
     
     
         19 . The isolated transformed host cell according to  claim 16 , wherein said polynucleotide is complementary along the full length of said polynucleotide of a). 
     
     
         20 . The isolated transformed host cell according to  claim 16 , wherein said polynucleotide is complementary along the full length of said polynucleotide of b). 
     
     
         21 . A method of making a polypeptide, comprising culturing an isolated transformed host cell according to  claim 11  under conditions that allow for the production of said polypeptide. 
     
     
         22 . The isolated or purified polynucleotide according to  claim 1 , wherein said HLA binding fragment has a length selected from the group consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, and 35 amino acids. 
     
     
         23 . The vector according to  claim 6 , wherein said HLA binding fragment has a length selected from the group consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, and 35 amino acids. 
     
     
         24 . The isolated transformed host cell according to  claim 11 , wherein said HLA binding fragment has a length selected from the group consisting of 8, 9, 10. 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, and 35 amino acids. 
     
     
         25 . The isolated transformed host cell according to  claim 16 , wherein said HLA binding fragment has a length selected from the group consisting of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, and 35 amino acids.